Results 161 to 170 of about 2,273,300 (329)

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

The Cost to Firms of Cooking the Books

open access: yesJournal of Financial and Quantitative Analysis, 2008
Jonathan M. Karpoff   +2 more
semanticscholar   +1 more source

Call for Papers: Rare Books Collections in Brazil: the founding collections and collection development policies

open access: yes, 2016
The National Library of Brazil and the National Rare Books Program Identification (Plano Nacional de Recuperação de Obras Raras), has announced the call for papers to the 12th National Meeting of Rare Books to be held 24th and 25th November 2016.
IFLA Rare Books & Special Collections Section
core  

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

Why Read New Books

open access: yes, 2014
The article considers raises the question, with so much excellent literature from the past, why should we read new books. It considers the differences, for a critic in particular, of reading new literature about which no criticism has yet been written ...
PARKS, TIMOTHY HAROLD
core  

Gender gaps in reading increase during unplanned and planned school closures. [PDF]

open access: yesProc Natl Acad Sci U S A
Smith E   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy